Po-Wei Chen
9 Papers
4 Citations
Po-Wei Chen is an academic researcher. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 1, co-authored 1 publications.
Chat about Author
Papers
Recent advances and clinical pharmacology aspects of Chimeric Antigen Receptor (CAR) T‐cellular therapy development
Johannes Kast,Saeideh Nozohouri,Di Zhou,Marc R. Yago,Po-Wei Chen,Malidi Ahamadi,Sandeep Dutta,Vijay V. Upreti +7 more
TL;DR: The current review presents an insight into the clinical pharmacology aspects of immuno‐therapies, especially CAR‐T cells, with particular focus on the structure of CAR‐ T cells, the effects and toxicities associated with these therapies in clinical trials, risk mitigation strategies, dose selection approaches, and cellular kinetics.
15
Pharmacokinetics and Pharmacokinetic/Pharmacodynamic Properties of Rozibafusp Alfa, a Bispecific Inhibitor of BAFF and ICOSL: Analyses of Phase I Clinical Trials
Lubna Abuqayyas,Po-Wei Chen,Marcia Cristina Teixeira Dos Santos,Jane R. Parnes,Sameer Doshi,Sandeep Dutta,Brett E. Houk +6 more
TL;DR: Rozibafusp alfa (AMG 570) is a bispecific IgG2-peptide fusion designed to inhibit inducible T-cell costimulator ligand (ICOSL) and B-cell activating factor (BAFF) as discussed by the authors .
9
Post hoc analysis of clinical trial data and pharmacokinetic data to assess wearing‐off of erenumab within monthly treatment cycle
David W. Dodick,Andrew M. Blumenfeld,Rashmi B. Halker Singh,Rachel Williams,Feng Zhang,Po-Wei Chen,Cheng Pang Hsu,Cheng Peng,Josefin Snellman,M. Chehrenama,Jessica Ailani +10 more
TL;DR: No systematic wearing-off with erenumab was identified and further research is needed to determine if wore-off reported for some patients in clinical practice reflects a true treatment response pattern or normal fluctuations in migraine frequency.
6
Immunogenicity of erenumab: A pooled analysis of six placebo-controlled trials with long-term extensions
Yanchen Zhou,Feng Zhang,Marta Starcevic Manning,Zheng Hu,Cheng Pang Hsu,Po-Wei Chen,Cheng Peng,B Loop,Daniel T. Mytych,Gabriel Paiva da Silva Lima +9 more
TL;DR: In this paper , an integrated post hoc analysis assessing immunogenicity of erenumab across six clinical trials in patients with episodic and chronic migraine was performed, and the authors concluded that immunogenity had no meaningful clinical impact on efficacy or safety of eernumab.
6